



Now enrolling: the VITESSE phase 3 study for peanut allergy



The VITESSE phase 3 study is evaluating an investigational drug patch to learn how well it works in children with peanut allergy. The investigational drug patch is not yet approved by the United States Food and Drug Administration, European Medicines Agency, or any other regulatory agencies.

To be eligible for this study, an individual must be:

- 4 to 7 years of age
- Diagnosed with peanut allergy
- Currently following a strict peanut-free diet

This is not a complete list of eligibility criteria. The study doctor will review the full entry criteria for this study with you. Eligible individuals will participate in the study for approximately 58 weeks (about 1 year).

Beth Kiernan
Clinical Research Coordinator
ekiernan@rchsd.org
858-966-1700 x224213

FLYER TEAR PAD
PLACED HERE



Ask your doctor about the
VITESSE study or scan the QR code.